The FDA approved Eli Lilly’s new weight-loss pill, setting up a fight with rival Novo Nordisk over the next front in the booming market https://t.co/1j0gqhoXlH ...

FDA Approves Eli Lilly’s Weight Loss Pill—Second Weight GLP-1 Drug In Pill Formhttps://t.co/p5uBtpdUYU https://t.co/DyOwW2Tpvb ...

Eli Lilly Chair & CEO Dave Ricks tells CNBC’s Angelica Peebles that with the approval of the company’s GLP-1 pill, orforglipron, they already have the scale necessary to supply the medicine to the globe. Ricks says that while 1 in 10 Americans are currently using a GLP-1, in China only 0.5% of the population has tried one, pointing to a large untapped market opportunity internationally. ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. https://t.co/FDknJHod96 ...

All right, let's get to it. A mad dash before we get you to the opening bell a little more than two minutes from now. Talk a little Lily.Of course, they did a deal a couple of days ago as well in the biotech area. >> You know, one of the things that you you kind your eyes glaze over these deals that are under 10 billion. They bought Centessa for 7.8% billion.I just said, "Oh, it's a sleep disorder thing." No, it's a peptide uh that impacts brain for many, many different ways, not just for sleep. And a lot o ...

Eli Lilly’s Zepbound is helping to solve one of the most intractable health challenges of our time: Obesity. Now, the drugmaker hopes to crack another significant public health problem: Sleep disorders. https://t.co/olBNCxJHzK ...

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Industry: Kahn Swick & Foti, LLC Mar 31, 2026 10:19 PM Eastern Daylight Time Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Share NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr. ...

Shares of Centessa Pharmaceuticals (CNTA +43.80%) surged on Tuesday after the drugmaker struck a deal to be acquired by Eli Lilly (LLY +3.55%) for as much as $7.8 billion. An enticing offer for Centessa's investorsUnder the terms of the deal, Lilly would purchase Centessa for $38 per share in cash. That's a premium of nearly 38% to the healthcare stock's closing price on Monday.Centessa's shareholders would also receive a non-transferrable contingent value right, which could be valued at up to $9 per share ...

Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion. The move is part of the former's plans to diversify its metabolic portfolio with sleep disorder treatments.Analysts chimed in on the update, with Needham and B. Riley downgrading CNTA to "hold" and "neutral," respectively, from "buy." Piper Sandler cut its rating to "neutral" from "overweight." Analysts were bullish coming into ...

Eli Lilly and Novo Nordisk, the two companies that dominate the global market for GLP-1 weight loss and diabetes drugs, are each deploying artificial intelligence (AI) across different stages of drug development in ways that are beginning to reshape how fast new medicines reach patients.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Compl ...